N-Acetyltransferase Phenotypes in the Urinary Bladder Carcinogenesis of a Low-risk Population
Overview
Authors
Affiliations
N-Acetyltransferase phenotypes were measured in 228 patients with tumours of the urinary bladder and 100 non-cancer controls. 63.6% of the patients and 54.0% of the controls were slow acetylator phenotypes (p less than 0.10). In general, 65% of bladder tumour patients and 59% of controls are slow acetylators (p less than 0.025). N-Acetyltransferases are involved in the metabolism of carcinogenic arylamines and thus could be an important factor in interindividual susceptibility to these agents.
Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis.
Zhu Z, Zhang J, Jiang W, Zhang X, Li Y, Xu X Onco Targets Ther. 2015; 8:3715-20.
PMID: 26715854 PMC: 4685932. DOI: 10.2147/OTT.S82927.
Challenges identifying genetic determinants of pediatric cancers--the childhood leukemia experience.
Sinnett D, Labuda D, Krajinovic M Fam Cancer. 2006; 5(1):35-47.
PMID: 16528607 DOI: 10.1007/s10689-005-2574-4.
Green J, Banks E, Berrington A, Darby S, Deo H, Newton R Br J Cancer. 2000; 83(3):412-7.
PMID: 10917561 PMC: 2374558. DOI: 10.1054/bjoc.2000.1265.
Hubbard A, Harrison D, Moyes C, Wyllie A, Cunningham C, Mannion E Gut. 1997; 41(2):229-34.
PMID: 9301503 PMC: 1891458. DOI: 10.1136/gut.41.2.229.
Arylamine N-acetyltransferase activity in human cultured cell lines.
Coroneos E, Sim E Biochem J. 1993; 294 ( Pt 2):481-6.
PMID: 8396914 PMC: 1134479. DOI: 10.1042/bj2940481.